What is the best approach to manage an elderly patient with a history of seizures, possible Lewy body dementia, and current symptoms of parkinsonism, who is taking Depakote (valproate), sertraline, and hydroxyzine, and experiencing tremor, coordination issues, agitation, and anger?

Management of Elderly Patient with Seizures, Possible Lewy Body Dementia, Parkinsonism, on Depakote, Sertraline, and Hydroxyzine

Direct Assessment of the Clinical Reasoning Presented

The clinical reasoning presented is largely accurate and well-founded, with important caveats regarding medication selection in possible Lewy body dementia. The concerns about Depakote-induced parkinsonism are valid, the recommendation to optimize sertraline is appropriate, and the plan to taper hydroxyzine is sound, though the specific approach to sertraline in possible DLB requires careful consideration. 1, 2

---

Critical Consideration: Lewy Body Dementia and Medication Sensitivity

Depakote (Valproate) and Parkinsonism

The concern about Depakote causing or worsening parkinsonian symptoms is well-founded and supported by strong evidence. 2, 3

• The FDA label explicitly lists tremor (25% incidence), Parkinsonism, ataxia (8%), and incoordination as known CNS adverse effects of valproate, particularly in elderly patients. 2
• In elderly patients with dementia, valproate causes significantly higher rates of somnolence, dehydration, reduced nutritional intake, and weight loss, with discontinuations for somnolence significantly higher than placebo. 2
• Two case reports document complete resolution of progressive cognitive impairment and parkinsonism after discontinuation of sodium valproate in elderly patients, with symptoms developing insidiously over months to years. 3
• The FDA specifically warns that in elderly patients, dosage should be increased more slowly with regular monitoring, and dose reductions or discontinuation should be considered in patients with decreased food or fluid intake and excessive somnolence. 2

The recommendation that neurology should re-evaluate whether a different anticonvulsant might be safer from a motor standpoint is appropriate and evidence-based. 4, 3

• Second-generation antiseizure medications are more likely to be appropriate for older patients with epilepsy and neurodegenerative disease given their more favorable pharmacokinetic profiles and lower risk of cognitive and motor adverse effects. 4
• The prescription of antiseizure medications in dementia must consider the potential neurocognitive and motor impact and limit it as much as possible. 4

---

Sertraline Optimization: Important Nuance for Possible DLB

The recommendation to increase sertraline gradually for agitation and anger is generally sound, but requires a critical caveat if Lewy body dementia is confirmed. 1, 5

Supporting Evidence for Sertraline in Dementia

• SSRIs, including sertraline, are recommended as first-line pharmacological treatment for chronic agitation in dementia, with the American Psychiatric Association recommending initiation at low dose and titration to minimum effective dose. 1
• Sertraline 25-50 mg/day (maximum 200 mg/day) is well-tolerated with less effect on metabolism of other medications and has significant benefits in reducing overall neuropsychiatric symptoms, agitation, and depression in dementia patients. 1
• The American Academy of Family Physicians recommends sertraline as a top choice for depression and anxiety in elderly patients due to minimal drug interactions and excellent tolerability. 1

Critical Warning for Lewy Body Dementia

However, there is a documented case report of sertraline-induced parkinsonism in a patient with prodromal dementia with Lewy bodies, with marked improvement after discontinuation. 5

• A 75-year-old man with prodromal DLB developed drug-induced parkinsonism after sertraline treatment, with parkinsonian symptoms improving markedly after discontinuation. 5
• The authors note there had been no prior reports of sertraline-induced or aggravated parkinsonian motor symptoms in DLB patients, making this a rare but documented phenomenon. 5

Therefore, if DLB is formally diagnosed, sertraline optimization should proceed with close monitoring for worsening motor symptoms, and alternative strategies should be considered if parkinsonism worsens. 5

---

Hydroxyzine Tapering: Strongly Supported

The recommendation to decrease hydroxyzine dose or move to as-needed use, then discontinue once sertraline is optimized, is strongly evidence-based and appropriate. 1

• Hydroxyzine is an anticholinergic medication that should be avoided in elderly dementia patients as it worsens confusion, agitation, tremor, coordination issues, sedation, and falls. 1
• The American Geriatrics Society recommends identifying and minimizing or discontinuing anticholinergic medications like hydroxyzine, which worsen confusion and agitation in dementia patients. 1
• At 25 mg three times daily (75 mg total daily), this represents a fairly high scheduled dose for someone this age, contributing to multiple adverse effects. 1

The plan to taper hydroxyzine gradually while optimizing sertraline is the correct approach, as abrupt discontinuation of chronic medications can cause withdrawal symptoms. 6

---

Lewy Body Dementia Diagnostic Considerations

The statement that there is a possibility of Lewy body dementia is clinically reasonable given the constellation of parkinsonian symptoms, tremor, coordination problems, and cognitive impairment. 7, 8

• DLB involves progressive memory loss, visual hallucinations, parkinsonism, cognitive fluctuations, and REM sleep behavior disorder, appearing in varying combinations and severity. 7
• Patients with DLB are very sensitive to antipsychotic medications, which can worsen motor and neuropsychiatric symptoms including cognition and psychosis, with intensity varying and potentially resulting in mortality. 8
• The median age of onset for DLB is 76.3 years, making this age-appropriate for consideration. 7

If DLB is suspected, the 5th Canadian Consensus Conference recommends considering SPECT DaT scans, which can help differentiate Lewy body dementia from other dementias. 6

---

Medication Management Algorithm

Step 1: Neurology Consultation for Depakote Re-evaluation

Request neurology to assess whether Depakote can be safely transitioned to a second-generation antiseizure medication with lower motor and cognitive adverse effect profile. 4, 3

• Do not stop or change abruptly due to seizure history—this requires neurologist guidance for safe transition. 4
• Monitor for improvement in tremor, coordination, and gait after any medication change. 3

Step 2: Hydroxyzine Taper

Begin gradual taper of hydroxyzine over 2-4 weeks, reducing by 25% of daily dose each week. 6, 1

• Start by reducing one dose (e.g., eliminate midday dose first, then morning, then evening). 6
• Monitor for withdrawal symptoms including rebound anxiety or insomnia. 6
• Move to as-needed use (maximum 12.5-25 mg) only for severe breakthrough agitation during taper. 1

Step 3: Sertraline Optimization with DLB Monitoring

Increase sertraline gradually from current dose toward target of 100-200 mg/day, but monitor closely for worsening motor symptoms if DLB is suspected. 1, 5

• Increase by 25-50 mg every 1-2 weeks as tolerated. 1
• Assess response using quantitative measures (Cohen-Mansfield Agitation Inventory or NPI-Q) within 4 weeks of reaching target dose. 1
• If parkinsonian symptoms worsen during sertraline titration, consider this may be sertraline-induced parkinsonism in DLB and discuss alternative strategies with neurology. 5
• If no clinically significant response after 4 weeks at adequate dose, taper and withdraw. 1

Step 4: Ongoing Monitoring

Monitor for fluid and nutritional intake, dehydration, somnolence, tremor, coordination, falls, and cognitive changes at every visit. 2

• Depakote requires monitoring for somnolence, dehydration, reduced nutritional intake, and weight loss in elderly patients. 2
• Assess for extrapyramidal symptoms, falls, and metabolic changes with any psychotropic medication. 1

---

Common Pitfalls to Avoid

Do not add antipsychotics if DLB is confirmed, as patients with DLB have severe neuroleptic sensitivity that can worsen motor and cognitive symptoms and increase mortality risk. 8

• If antipsychotic treatment becomes absolutely necessary for severe psychosis threatening harm, pimavanserin may be the safest option in DLB, though it still carries increased mortality risk. 7, 8
• Typical antipsychotics and even atypical antipsychotics like olanzapine can cause severe worsening of motor and cognitive function in DLB. 8

Do not continue hydroxyzine long-term—anticholinergic medications worsen agitation, cognition, and motor function in dementia patients. 1

Do not assume all agitation requires medication—systematically investigate and treat reversible causes including pain, infections (UTI, pneumonia), constipation, urinary retention, and dehydration first. 1, 9, 10

If sertraline causes or worsens parkinsonism in confirmed DLB, do not persist with escalation—consider alternative non-pharmacological strategies or consultation with dementia specialist. 5